These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31345074)

  • 1. Magmaris resorbable magnesium scaffold for the treatment of coronary heart disease: overview of its safety and efficacy.
    Bennett J; De Hemptinne Q; McCutcheon K
    Expert Rev Med Devices; 2019 Sep; 16(9):757-769. PubMed ID: 31345074
    [No Abstract]   [Full Text] [Related]  

  • 2. The Resorbable Magnesium Scaffold Magmaris in Acute Coronary Syndrome: An Appraisal of Evidence and User Group Guidance.
    Bennett J; Ielasi A; Torzewski J; de Hemptinne Q; Cerrato E; Lanocha M; Galli S; Sabaté M
    Cardiovasc Revasc Med; 2022 Jun; 39():106-113. PubMed ID: 34629285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The coronary resorbable magnesium scaffold Magmaris®: what we have learnt (so far…).
    Bennett J; McCUTCHEON K
    Minerva Cardiol Angiol; 2021 Apr; 69(2):215-221. PubMed ID: 32326679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives.
    Brugaletta S; Garcia-Garcia HM; Onuma Y; Serruys PW
    Expert Rev Med Devices; 2012 Jul; 9(4):327-38. PubMed ID: 22420293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SICI-GISE Position Document on the Use of the Magmaris Resorbable Magnesium Scaffold in Clinical Practice.
    Galli S; Testa L; Montorsi P; Bedogni F; Pisano F; Palloshi A; Mauro C; Contarini M; Varbella F; Esposito G; Caramanno G; Secco GG; D'Amico G; Musumeci G; Tarantini G
    Cardiovasc Revasc Med; 2022 Jan; 34():11-16. PubMed ID: 33674219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bioresorbable magnesium scaffold (Magmaris)-State of the art: From basic concept to clinical application.
    Rola P; Włodarczak S; Doroszko A; Lesiak M; Włodarczak A
    Catheter Cardiovasc Interv; 2022 Nov; 100(6):1051-1058. PubMed ID: 36229949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model.
    Waksman R; Zumstein P; Pritsch M; Wittchow E; Haude M; Lapointe-Corriveau C; Leclerc G; Joner M
    EuroIntervention; 2017 Jul; 13(4):440-449. PubMed ID: 28262623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [SICI-GISE Position paper on the use of the magnesium bioresorbable scaffold Magmaris in clinical practice].
    Galli S; Testa L; Montorsi P; Bedogni F; Pisano F; Palloshi A; Mauro C; Contarini M; Varbella F; Esposito G; Caramanno G; Secco GG; D'Amico G; Musumeci G; Tarantini G
    G Ital Cardiol (Rome); 2020 Feb; 21(2 Suppl 1):52S-59S. PubMed ID: 32134409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnesium 2000 postmarket evaluation: Guideline adherence and intraprocedural performance of a sirolimus-eluting resorbable magnesium scaffold.
    Wlodarczak A; Garcia LAI; Karjalainen PP; Komócsi A; Pisano F; Richter S; Lanocha M; Rumoroso JR; Leung KF
    Cardiovasc Revasc Med; 2019 Dec; 20(12):1140-1145. PubMed ID: 30833209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
    Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
    Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State of the art: the inception, advent and future of fully bioresorbable scaffolds.
    Katagiri Y; Stone GW; Onuma Y; Serruys PW
    EuroIntervention; 2017 Aug; 13(6):734-750. PubMed ID: 28844034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds - magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort.
    Włodarczak A; Rola P; Barycki M; Furtan Ł; Łanocha M; Włodarczak S; Szudrowicz M; Kulczycki JJ; Jaroszewska-Pozorska J; Kędzierska M; Giniewicz K; Doroszko A; Lesiak M
    Diab Vasc Dis Res; 2023; 20(4):14791641231188705. PubMed ID: 37439002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study.
    Haude M; Wlodarczak A; van der Schaaf RJ; Torzewski J; Ferdinande B; Escaned J; Iglesias JF; Bennett J; Toth GG; Joner M; Toelg R; Wiemer M; Olivecrano G; Vermeersch P; Garcia-Garcia HM; Waksman R
    EuroIntervention; 2023 Aug; 19(5):e414-e422. PubMed ID: 37334655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds: Magmaris Versus Absorb in a Porcine Arteriovenous Shunt Model.
    Waksman R; Lipinski MJ; Acampado E; Cheng Q; Adams L; Torii S; Gai J; Torguson R; Hellinga DM; Westman PC; Joner M; Zumstein P; Kolodgie FD; Virmani R
    Circ Cardiovasc Interv; 2017 Aug; 10(8):. PubMed ID: 28801538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-Eluting Resorbable Magnesium Scaffold Implantation in ST-Segment Elevation Myocardial Infarction: A Pilot Study.
    de Hemptinne Q; Picard F; Briki R; Awada A; Silance PG; Dolatabadi D; Debbas N; Unger P
    J Invasive Cardiol; 2018 Jun; 30(6):202-206. PubMed ID: 29656279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioresorbable scaffold technologies.
    Onuma Y; Ormiston J; Serruys PW
    Circ J; 2011; 75(3):509-20. PubMed ID: 21301138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.